Alex Kudrin MD, MBA, PhD

Dr Alex Kudrin has graduated Orenburg Medical Academy in Russia in 1997 and received PhD / MD in Respiratory Medicine and Immunology from Moscow Medical University (2001) and MBA from Westminster University in London (2011). He was employed at Acambis, GlaxoSmithKline, GlaxoSmithKline Biologicals and Takeda Global R&D at various senior positions in clinical development of novel anti-inflammatory agents and vaccines. Between 2007-2012, he was appointed as a Medical Assessor in Biological PLAT of Licensing Division at MHRA in London participating in clinical evaluation, scientific advice and approval of various biotechnology products, including monoclonal antibodies, vaccines, blood products, and advanced cell therapies. Since September 2013 till March 2016 he held position of a Vice-President and Head of Global Development at Celltrion Inc in Korea leading development efforts for Remsima/Inflectra and approvals in the US, EU, Canada, Australia and other territories. He has also led development of biosimilar rituximab and trastuzumab candidates. Currently he is biopharmaceutical consultant based in the UK. Dr Kudrin has specific interests in biosimilars, oncology, immunology, vaccines; clinical development, emerging markets in Asia, Latin America and Russia. He is an author of 70 publications including 5 books on immunopharmacology, immunopathology and immunology of cancer.